Latest Pharmaceuticals News

Althea Group Holdings Limited has had its trading suspension lifted following a Federal Court ruling related to cleansing notice lodgement failures, marking a key regulatory milestone for the pharmaceutical company.

Sigma Healthcare has received Federal Court approval for its acquisition of Chemist Warehouse, marking a pivotal step in its strategic expansion. The scheme is set to become legally effective on February 4, 2025, with implementation expected by February 12.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

Cardiex has kicked off deliveries of its CONNEQT Pulse arterial health monitors in the U.S., reporting strong preorder momentum and a 150% sales increase in December. The company’s strategic operational shifts and pharma partnerships set the stage for sustained growth in 2025.

Althea Group Holdings has obtained Federal Court orders confirming the validity of past share sales despite previous failures to lodge required Cleansing Notices, paving the way for the reinstatement of its shares to trading.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.

Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.

Wellnex Life Limited reported a 36% rise in Q2 FY25 cash receipts and record monthly sales, while advancing its dual listing on the London Stock Exchange and expanding into the UK market.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Althea Group Holdings reported a 20% increase in customer receipts to $9.01 million for Q2 FY25, while addressing governance lapses and reviewing its FY25 guidance. The company is advancing operational improvements and cost savings as it prepares for a pivotal Federal Court hearing.